123 related articles for article (PubMed ID: 38215590)
1. Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer.
Lai R; Lin Z; Yang C; Hai L; Yang Z; Guo L; Nie R; Wu Y
Eur J Med Chem; 2024 Feb; 266():116116. PubMed ID: 38215590
[TBL] [Abstract][Full Text] [Related]
2. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
4. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
5. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
Gou P; Zhang W
Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
[TBL] [Abstract][Full Text] [Related]
6. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.
Stimson L; Rowlands MG; Newbatt YM; Smith NF; Raynaud FI; Rogers P; Bavetsias V; Gorsuch S; Jarman M; Bannister A; Kouzarides T; McDonald E; Workman P; Aherne GW
Mol Cancer Ther; 2005 Oct; 4(10):1521-32. PubMed ID: 16227401
[TBL] [Abstract][Full Text] [Related]
7. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
8. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.
Balasubramanyam K; Varier RA; Altaf M; Swaminathan V; Siddappa NB; Ranga U; Kundu TK
J Biol Chem; 2004 Dec; 279(49):51163-71. PubMed ID: 15383533
[TBL] [Abstract][Full Text] [Related]
9. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy.
Dai Q; Yuan Z; Sun Q; Ao Z; He B; Jiang Y
Bioorg Med Chem Lett; 2024 May; 104():129742. PubMed ID: 38604299
[TBL] [Abstract][Full Text] [Related]
11. Histone acetyltransferase promotes fluoride toxicity in LS8 cells.
Deng H; Fujiwara N; Cui H; Whitford GM; Bartlett JD; Suzuki M
Chemosphere; 2020 May; 247():125825. PubMed ID: 31927229
[TBL] [Abstract][Full Text] [Related]
12. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
13. Characterization of novel inhibitors of histone acetyltransferases.
Eliseeva ED; Valkov V; Jung M; Jung MO
Mol Cancer Ther; 2007 Sep; 6(9):2391-8. PubMed ID: 17876038
[TBL] [Abstract][Full Text] [Related]
14. Concomitant increase of histone acetyltransferase activity and degradation of p300 during retinoic acid-induced differentiation of F9 cells.
Brouillard F; Cremisi CE
J Biol Chem; 2003 Oct; 278(41):39509-16. PubMed ID: 12888559
[TBL] [Abstract][Full Text] [Related]
15. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells.
Su M; Bansal AK; Mantovani R; Sodek J
J Biol Chem; 2005 Nov; 280(46):38365-75. PubMed ID: 16087680
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid exposure decreases Cbp/p300 protein expression and histone acetyltransferase activity in P19 cells.
Lamparter CL; Winn LM
Toxicol Appl Pharmacol; 2016 Sep; 306():69-78. PubMed ID: 27381264
[TBL] [Abstract][Full Text] [Related]
18. E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP.
Fax P; Lehmkuhler O; Kuhn C; Esche H; Brockmann D
J Biol Chem; 2000 Dec; 275(51):40554-60. PubMed ID: 11006273
[TBL] [Abstract][Full Text] [Related]
19. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
20. Human interleukin-5 expression is synergistically regulated by histone acetyltransferase CBP/p300 and transcription factors C/EBP, NF-AT and AP-1.
Liu C; Lu J; Tan J; Li L; Huang B
Cytokine; 2004 Aug 21-Sep 7; 27(4-5):93-100. PubMed ID: 15271374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
